Neovasc Inc. ROE

ROE of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2021 was -91.12% (a -118.68% decrease from previous year)
  • Annual ROE for 2020 was 487.79% (a 54.93% increase from previous year)
  • Annual ROE for 2019 was 314.85% (a -31.27% decrease from previous year)
  • Twelve month ROE ending March 31, 2022 was -56.61% (a -38.21% decrease compared to previous quarter)
  • Twelve month trailing ROE decreased by -38.55% year-over-year
Trailing ROE for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-56.61% -91.62% -79.63% -92.13%
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Neovasc Inc.

Most recent ROEof NVCN including historical data for past 10 years.

Interactive Chart of ROE of Neovasc Inc.

Neovasc Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -91.12%
2020 487.79%
2019 314.85%
2018 458.11%
2017 91.45%
2016 -406.72%
2015 -70.32%
2014 -146.25%
2013 -101.47%
2012 -5.46%
2011 -60.17%

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.